About Alpha-amylase 2B
Alpha-amylase 2B (AMY2B) is a protein
from Homo sapiens identified by UniProt accession
P19961, 511 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | Alpha-amylase 2B |
| UniProt accession | P19961 |
| Gene | AMY2B |
| Organism | Homo sapiens |
| Length | 511 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (32)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.39
- dentures · score 0.23
- lung adenocarcinoma · score 0.18
- squamous cell lung carcinoma · score 0.18
- head and neck squamous cell carcinoma · score 0.18
- cutaneous melanoma · score 0.18
- endometrial cancer · score 0.18
- dental caries · score 0.18
- esophageal cancer · score 0.11
- diabetes mellitus · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P19961-F1 | alphafold | PREDICTED | 96.77 | — |
Amino-acid sequence (511 residues)
MKFFLLLFTI GFCWAQYSPN TQQGRTSIVH LFEWRWVDIA LECERYLAPK GFGGVQVSPP NENVAIHNPF RPWWERYQPV SYKLCTRSGN EDEFRNMVTR CNNVGVRIYV DAVINHMSGN AVSAGTSSTC GSYFNPGSRD FPAVPYSGWD FNDGKCKTGS GDIENYNDAT QVRDCRLVGL LDLALEKDYV RSKIAEYMNH LIDIGVAGFR LDASKHMWPG DIKAILDKLH NLNSNWFPAG SKPFIYQEVI DLGGEPIKSS DYFGNGRVTE FKYGAKLGTV IRKWNGEKMS YLKNWGEGWG FMPSDRALVF VDNHDNQRGH GAGGASILTF WDARLYKMAV GFMLAHPYGF TRVMSSYRWP RQFQNGNDVN DWVGPPNNNG VIKEVTINPD TTCGNDWVCE HRWRQIRNMV NFRNVVDGQP FTNWYDNGSN QVAFGRGNRG FIVFNNDDWT FSLTLQTGLP AGTYCDVISG DKINGNCTGI KIYVSDDGKA HFSISNSAED PFIAIHAESK L
Explore Alpha-amylase 2B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets